While TRAIL is relatively non-toxic to normal cells, it can selectively induce apoptosis in many types of transformed cells. Nevertheless, some non-small cell lung cancer (NSCLC) cells are particularly resistant to the effects of TRAIL. Here, we report that in combination with naringenin exposure to
Inhibition of novel protein kinase Cɛ augments TRAIL-induced cell death in A549 lung cancer cells
✍ Scribed by Matthias Felber; Jürgen Sonnemann; James F Beck
- Publisher
- Springer Netherlands
- Year
- 2007
- Tongue
- English
- Weight
- 757 KB
- Volume
- 13
- Category
- Article
- ISSN
- 1219-4956
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
I 2-0-tetradecanoylphorbol-I 3-acetate (TPA) and bryostatin I are activators of protein kinase C (PKC). TPA is a potent inhibitor of the growth of A549 cells, while bryostatin I exerts a weak antiproliferative effect upon this cell line. We tested the hypothesis that the PKC inhibitor staurosporine
## Abstract A vast variety of naturally occurring substances have been shown to protect against experimental carcinogenesis and an increasing amount of evidence suggests that kaempferol may have cancer chemopreventative properties. However, the precise underlying protective mechanisms are poorly un
Multidrug resistance (MDR) is a major impediment to successful chemotherapy for lung cancer. Overexpression of multidrug resistance-associated protein 1 (MRP1) appears to be involved in MDR development in lung cancer cells. A number of chemotherapeutic agents including doxorubicin (DOX) were reporte
## Abstract Approximately 25% of patients with colorectal cancer will develop metastatic disease exclusively or largely confined to the liver, and the vast majority of these cases are not amenable to surgical resection. These unresectable cases of liver metastatic disease can be treated with isolat